HDAC9 and T-cell non-Hodgkin lymphoma: HDAC1 has been served as a target for cancer therapy, and small molecule HDAC inhibitors have been used in clinical treatment of patients with several types of cancer, such as T-cell lymphoma and multiple myeloma currently.